QoL in LSSCNCT07320820
Quality of Life and Functional Outcomes in Laryngeal Cancer Patients
At risk: Primary completion moved 6 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Jan 2, 2027 to Jul 2, 2027 Show 4 more changesShow less
- Start date: Apr 2, 2026 to Jan 2, 2027
- Eligibility criteria expanded, about 9 words
- Primary endpoints: details revised at 1 of 1 entry
- Secondary endpoints: details revised at 7 of 7 entries
- Notable Start date: Jan 2, 2026 to Apr 2, 2026v2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
This group includes patients with laryngeal squamous cell carcinoma who undergo primary surgical treatment, such as partial or total laryngectomy, with or without neck dissection, in accordance with standard oncological indications. Patients in this group may receive adjuvant radiotherapy or chemoradiotherapy when clinically indicated based on pathological findings.
This group consists of patients with laryngeal squamous cell carcinoma treated with definitive radiotherapy as the primary treatment modality. Radiotherapy is delivered according to established clinical protocols, and no surgical intervention to the primary tumor is performed as the initial treatment.
This group includes patients with laryngeal squamous cell carcinoma who receive concurrent chemoradiotherapy as the primary treatment modality, typically for organ preservation purposes or in locally advanced disease. Chemotherapy is administered concurrently with radiotherapy in accordance with institutional and international treatment guidelines.
Other: Quality of Life Assessment, Patient Satisfaction Assessment, Swallowing Function Assessment, Voice Assessment, Pain Assessment, Anxiety and Depression Assessment